Pharmaceutical
ChemLinkedChemicalFoodCosmeticPharmaceuticalJapanAgrochemicalSustainability
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
INDUSTRY
Law & Regulation Pharmacopoeia MAH Pharmacovigilance Marketing Approval Innovative Drug Drug Registration New Drug
CRAC-HCF 2021 | Embracing China's Pharma Market With Regulatory Compliance and Industry Insights Five experts from drug regulation authorities, pharmaceutical companies, and consulting firms decoded drug regulations and analyzed industry dynamics for international pharma companies to develop businesses in the Chinese market.
Nov 17, 2021
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Biosimilar Drug Registration New Drug
Monthly Report: New Drug Approvals in China | Oct. 2021 In Oct. 2021, China's NMPA granted marketing authorization approvals to 11 new drugs, including Takeda's VOCINTI and Sanofi's Clopidogrel Bisulfate and Aspirin Tablets.
Nov 08, 2021
INDUSTRY
Law & Regulation Biological Product Injection
NMPA-Approved Injectable Fillers in China's Market China’s promising injectable filler market is expected to witness other new products' emergence. The market size is predicted to grow from US$ 603.8 million in 2019 to US$ 1,063.53 million by 2026. Meanwhile, China tightens the regulation on aesthetic medical products or practices so injectable fillers and relevant businesses won’t be an exception.
Nov 04, 2021
INDUSTRY
Marketing Approval Innovative Drug Generic Drug Biological Product Biosimilar Drug Registration New Drug
Monthly Report: New Drug Approvals in China | Sept. 2021 In Sept. 2021, China's NMPA granted 13 new drug approvals, including for Sanofi-Aventis Groupe's Dupilumab Injection and Merck's Pembrolizumab Injection.
Oct 25, 2021
INDUSTRY
Law & Regulation Pharmacopoeia MAH Pharmacovigilance Marketing Approval Innovative Drug Drug Registration New Drug
Online Conference | China Drug Regulation and Pharmaceutical Market BaiPharm will hold a virtual conference on Nov. 12, as part of the CRAC-HCF 2021 event. We will have five speeches elaborating on China drug regulations and pharmaceutical market. The specific topics include China market entry strategy, Chinese Pharmacopoeia, GVP, MAH, and innovative drug research.
Oct 21, 2021
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Drug Registration New Drug
Monthly Report: New Drug Approvals in China | Aug. 2021 In Aug. 2021, China NMPA nodded for nine new drug products including Tislelizumab Injection, Apremilast Tablet and Nivolumab Injection.
Sep 14, 2021
INDUSTRY
Marketing Approval Drug Registration
Monthly Report: New Drug Approvals in China | July 2021 In July 2021, China NMPA granted 14 new drug approvals for ten imported products and four domestic ones.
Aug 16, 2021
INDUSTRY
Marketing Approval Innovative Drug Generic Drug New Drug
Monthly Report: New Drug Approvals in China | June 2021 In June 2021, China NMPA granted 21 new drug approvals.
Jul 14, 2021
INDUSTRY
Marketing Approval Cell Therapy Gene Therapy
China Approves First Domestic CAR-T Therapy Fosun Kite's Axicabtagene Ciloleucel recently received marketing authorization by NMPA, becoming the first CAR-T therapy approved in China. The Chinese CAR-T industry is thus eyeing a promising future, but the road to market success is challenging.
Jul 12, 2021
INDUSTRY
Marketing Approval Priority Review Drug Registration New Drug
Monthly Report: New Drug Approvals in China | May 2021 In May 2021, China NMPA granted approvals to a total of nine innovative new drugs, improved new drugs, imported original drugs and first generics.
Jun 15, 2021
Pre 1... 56789 Next
Most Popular